Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $44,044 | $37,929 | $30,015 | $30,542 |
| % Growth | 16.1% | 26.4% | -1.7% | – |
| Cost of Goods Sold | $2,113 | $1,051 | $1,301 | $1,331 |
| Gross Profit | $41,931 | $36,878 | $28,714 | $29,211 |
| % Margin | 95.2% | 97.2% | 95.7% | 95.6% |
| R&D Expenses | $30,544 | $32,788 | $34,618 | $33,302 |
| G&A Expenses | $0 | $28,477 | $27,352 | $27,190 |
| SG&A Expenses | $26,607 | $28,477 | $27,352 | $27,190 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $57,151 | $61,265 | $61,970 | $60,492 |
| Operating Income | -$15,220 | -$24,387 | -$33,256 | -$31,281 |
| % Margin | -34.6% | -64.3% | -110.8% | -102.4% |
| Other Income/Exp. Net | -$17,873 | -$12,825 | $9,830 | $392 |
| Pre-Tax Income | -$33,093 | -$37,212 | -$23,426 | -$30,889 |
| Tax Expense | $34 | $40 | $36 | -$109 |
| Net Income | -$33,127 | -$37,252 | -$23,462 | -$30,780 |
| % Margin | -75.2% | -98.2% | -78.2% | -100.8% |
| EPS | -3.82 | -4.32 | -2.77 | -3.67 |
| % Growth | 11.6% | -56% | 24.5% | – |
| EPS Diluted | -3.82 | -4.32 | -2.77 | -3.67 |
| Weighted Avg Shares Out | 8,669 | 8,620 | 8,470 | 8,392 |
| Weighted Avg Shares Out Dil | 8,669 | 8,620 | 8,470 | 8,392 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $613 | $1,000 | $1,482 |
| Interest Expense | $10,455 | $11,228 | $10,994 | $11,204 |
| Depreciation & Amortization | $78 | $78 | $78 | $81 |
| EBITDA | -$22,560 | -$25,906 | -$12,354 | -$19,604 |
| % Margin | -51.2% | -68.3% | -41.2% | -64.2% |